OTCMKTS:BRTX BioRestorative Therapies (BRTX) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free BRTX Stock Alerts $1.46 +0.09 (+6.57%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$1.28▼$1.4950-Day Range$1.23▼$1.5052-Week Range$1.20▼$7.13Volume363,272 shsAverage Volume714,590 shsMarket Capitalization$9.88 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC Filings Get BioRestorative Therapies alerts: Email Address BioRestorative Therapies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside927.4% Upside$15.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.18Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.52) to ($2.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.75 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBioRestorative Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioRestorative Therapies has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BRTX. Previous Next 0.0 Dividend Strength Dividend YieldBioRestorative Therapies does not currently pay a dividend.Dividend GrowthBioRestorative Therapies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BRTX. Previous Next 1.6 News and Social Media Coverage News SentimentBioRestorative Therapies has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BioRestorative Therapies this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for BRTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added BioRestorative Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioRestorative Therapies insiders have not sold or bought any company stock.Percentage Held by Insiders21.60% of the stock of BioRestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.38% of the stock of BioRestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioRestorative Therapies are expected to grow in the coming year, from ($3.52) to ($2.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioRestorative Therapies is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioRestorative Therapies is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioRestorative Therapies has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About BioRestorative Therapies Stock (OTCMKTS:BRTX)BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Read More BRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRTX Stock News HeadlinesMay 3, 2024 | americanbankingnews.comCritical Survey: BioRestorative Therapies (BRTX) & Its CompetitorsMay 2, 2024 | americanbankingnews.comFinancial Review: BioRestorative Therapies (BRTX) vs. Its PeersMay 3, 2024 | Allegiance Gold (Ad)Could Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.May 2, 2024 | americanbankingnews.comBioRestorative Therapies (BRTX) and The Competition Critical ContrastApril 28, 2024 | americanbankingnews.comFinancial Survey: BioRestorative Therapies (BRTX) versus Its PeersApril 23, 2024 | americanbankingnews.comBioRestorative Therapies (BRTX) vs. Its Peers Critical SurveyApril 19, 2024 | markets.businessinsider.comOptimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic AdvancesApril 17, 2024 | msn.comBioRestorative Therapies (BRTX) Price Target Decreased by 16.00% to 10.71May 3, 2024 | Allegiance Gold (Ad)Could Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.April 14, 2024 | finance.yahoo.com10 Micro-Cap Healthcare Stocks Insiders Are BuyingFebruary 16, 2024 | investing.comBioRestorative Therapies Inc (BRTX)February 14, 2024 | finanznachrichten.deBioRestorative Therapies, Inc.: BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society 2024 Annual MeetingFebruary 6, 2024 | msn.comPRSO, AKRO and MIRA among pre-market losersDecember 20, 2023 | forbes.comGut Health Could Play A Role In How Blood Cancer Patients Respond To New TherapiesDecember 12, 2023 | marketwatch.comBioRestorative Therapies Shares Rise 14% on Allowance for Patent ApplicationDecember 12, 2023 | finance.yahoo.comBioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity ProgramNovember 9, 2023 | cnet.comBest Light Therapy Lamps for 2023October 9, 2023 | finance.yahoo.comBioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York CitySeptember 18, 2023 | seekingalpha.comBioRestorative Therapies' 10% shareholder Broadrick Dale increases holdingSeptember 18, 2023 | finance.yahoo.comRoth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”September 12, 2023 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Enters into Supply Agreement with Evolutionary BiologicsSeptember 12, 2023 | stockhouse.comBioRestorative Therapies Enters into Supply Agreement with Evolutionary BiologicsSeptember 8, 2023 | finance.yahoo.comBioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc DiseaseAugust 30, 2023 | msn.com$BRTX Is Looking To Treat Chronic Pain Without The Need For Class-A DrugsAugust 29, 2023 | benzinga.comAs America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A DrugsAugust 15, 2023 | msn.comRoth MKM Reiterates BioRestorative Therapies (BRTX) Buy RecommendationAugust 8, 2023 | finance.yahoo.comMirati (MRTX) Reports Q2 Loss, Misses Revenue EstimatesSee More Headlines Receive BRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:BRTX CUSIPN/A CIK1505497 Webwww.biorestorative.com Phone(631) 760-8100FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+927.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,500,000.00 Net Margins-13,728.83% Pretax Margin-13,728.83% Return on Equity-120.47% Return on Assets-114.48% Debt Debt-to-Equity RatioN/A Current Ratio14.81 Quick Ratio14.81 Sales & Book Value Annual Sales$145,800.00 Price / Sales67.79 Cash FlowN/A Price / Cash FlowN/A Book Value$2.65 per share Price / Book0.55Miscellaneous Outstanding Shares6,770,000Free Float3,660,000Market Cap$9.88 million OptionableNot Optionable Beta61.51 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Lance Alstodt (Age 53)Chairman of the Board, President & CEO Comp: $954.17kMr. Robert Eugene Kristal (Age 56)Chief Financial Officer Comp: $368.12kMr. Francisco J. Silva (Age 49)Chief Scientist, VP of Research & Development, Secretary and Director Comp: $891.67kMr. Robert Paccasassi (Age 55)Vice President of Quality Assurance & Regulatory Compliance Comp: $233.95kDr. Wayne J. Olan M.D.Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory BoardKey CompetitorsPHAXIAM TherapeuticsNASDAQ:PHXMEnveric BiosciencesNASDAQ:ENVBTherapix BiosciencesOTCMKTS:TRPXYiBioNYSEMKT:IBIOWindtree TherapeuticsNASDAQ:WINTView All CompetitorsInsidersDale BroadrickBought 1,000 shares on 7/27/2023Total: $2,800.00 ($2.80/share)Lance AlstodtBought 4,200 shares on 7/25/2023Total: $10,248.00 ($2.44/share)View All Insider Transactions BRTX Stock Analysis - Frequently Asked Questions Should I buy or sell BioRestorative Therapies stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BRTX shares. View BRTX analyst ratings or view top-rated stocks. What is BioRestorative Therapies' stock price target for 2024? 1 Wall Street analysts have issued twelve-month price targets for BioRestorative Therapies' shares. Their BRTX share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 927.4% from the stock's current price. View analysts price targets for BRTX or view top-rated stocks among Wall Street analysts. How have BRTX shares performed in 2024? BioRestorative Therapies' stock was trading at $1.7399 at the start of the year. Since then, BRTX stock has decreased by 16.1% and is now trading at $1.46. View the best growth stocks for 2024 here. How were BioRestorative Therapies' earnings last quarter? BioRestorative Therapies, Inc. (OTCMKTS:BRTX) announced its earnings results on Friday, March, 29th. The company reported ($0.57) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.03 million. BioRestorative Therapies had a negative net margin of 13,728.83% and a negative trailing twelve-month return on equity of 120.47%. When did BioRestorative Therapies' stock split? BioRestorative Therapies shares reverse split before market open on Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. What other stocks do shareholders of BioRestorative Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), OPKO Health (OPK). How do I buy shares of BioRestorative Therapies? Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BRTX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersThe AI Stock that’s Disrupting Every IndustryStockEarningsUrgent Nvidia WarningAltimetryCould Your Accounts Be Frozen?Allegiance GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profits$5,000 Gold?Stansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioRestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
